Retatrutide vs Tirzepatide: Research Context
Retatrutide and Tirzepatide are separate research entities with different receptor-pathway profiles. This page compares verifiable identifiers and study context without making efficacy or human-use claims.
Last reviewed:
Warning: These materials are strictly for in-vitro laboratory research. Not for human or veterinary use.
Entity distinction
Retatrutide is identified as LY3437943 and is described in publications as acting across GIP, GLP-1 and glucagon receptor pathways. Tirzepatide is identified as LY3298176 and is associated with GIP and GLP-1 receptor pathways. These identifiers should not be treated as interchangeable.
Direct comparison research
ClinicalTrials.gov record NCT06662383 documents a randomized study designed to compare Retatrutide with Tirzepatide. The existence of that protocol confirms an active comparison question; it should not be presented as a completed result or superiority claim.
Laboratory documentation
A useful laboratory comparison separates molecular identity, nominal material amount and batch-specific analytical evidence. Study records do not replace the Certificate of Analysis or other documentation attached to a supplied batch.
Research references
- Retatrutide Compared to Tirzepatide in Adults Who Have Obesity — ClinicalTrials.gov, NCT06662383
- Retatrutide, a GIP, GLP-1 and glucagon receptor agonist: a phase 2 trial — The Lancet / PubMed, PMID 37385280
Reference questions
Does a different receptor profile establish which material is better?
No. A receptor profile describes a research distinction. It does not by itself establish superiority, suitability for a protocol or any human-use conclusion.